Clinical Trials Directory

Trials / Completed

CompletedNCT06694896

Microarray Application in Newborns With Multiple Congenital Anomalies

Microarray Application in Newborns With Multiple Congenital Anomalies: Genotype-Phenotype Correlation

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
63 (actual)
Sponsor
Konya City Hospital · Academic / Other
Sex
All
Age
1 Day – 30 Days
Healthy volunteers
Not accepted

Summary

Objective: Congenital anomalies are defined as abnormalities of body structure or function that are present at birth and have developed prenatally. Microarray is considered the first-tier diagnostic test for patients with multiple congenital anomalies. The aim of this study is to determine the relationship between microarray results and the phenotype in newborns with multiple congenital anomalies, contribute to patient management by comparing with similar cases in the literature, detect previously unidentified Copy Number Variations (CNV), investigate the hereditary origin of the detected changes, and provide appropriate genetic counseling.

Detailed description

Method: Between December 2022 and November 2023, newborns with multiple congenital anomalies requiring follow-up and treatment in the Neonatal Intensive Care Unit of Konya City Hospital were evaluated. Newborns with examination findings suggesting a recognizable numerical chromosome anomaly or a history of teratogenicity were excluded from the study. Newborns with two major or one major and two minor, or three or more minor congenital anomalies were included. Microarray studies were performed on patients who met the inclusion criteria. CNVs identified were examined in relevant databases, and pathogenicity was assessed. Detected alterations were compared with the clinical findings in the patient database.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTMicroarray ApplicationMicroarray studies were performed on patients who met the inclusion criteria. CNVs identified were examined in relevant databases, and pathogenicity was assessed. Detected alterations were compared with the clinical findings in the patient database.

Timeline

Start date
2022-12-01
Primary completion
2023-11-29
Completion
2024-03-31
First posted
2024-11-19
Last updated
2024-11-19

Locations

1 site across 1 country: Turkey (Türkiye)

Source: ClinicalTrials.gov record NCT06694896. Inclusion in this directory is not an endorsement.